iPS Cells & Regenerative Medicine– category –
-
Unicorn Bioscience Report Projects Regenerative Medicine Market to Reach $58.4 Billion in 2026, Scaling to $360 Billion by 2034
Unicorn Bioscience USA Overview Unicorn Bioscience has published a market research report projecting the regenerative medicine market to reach approximately $58.4 billion in 2026, with an anticipated surge to $360 billion by 2034. This g... -
First-in-Human Pluripotent Stem Cell-Derived Neural Stem Cell Therapy for Huntington’s Disease (Regen4HD) Reports Phase 1b/2a Updates at ISSCR 2026
PharmaTimes USA Overview Updates from the first-in-human Phase 1b/2a clinical trial of Regen4HD, a pluripotent stem cell-derived neural stem cell therapy for Huntington's disease, were presented at the ISSCR 2026 Annual Meeting. This lan... -
MSC-Derived Exosomes Emerge as Promising Cell-Free Regenerative Therapies, Driving Active Research in Arthritis, Chronic Wounds, and Inflammatory Diseases
Vertex AI Search USA Overview Mesenchymal Stem Cell (MSC)-derived exosomes are garnering significant attention in regenerative medicine as a cell-free therapeutic alternative, capable of delivering MSCs' potent regenerative and immunomod... -
CRISPR Gene Therapies Expand Beyond Initial FDA Approvals, Advancing to Late-Stage Trials for Diverse Indications
Ubie Doctor's Note USA Overview As of mid-2026, two CRISPR gene therapies, Casgevy (for sickle cell disease and beta-thalassemia) and EDIT-101 (for Leber congenital amaurosis type 10), have received FDA approval, establishing foundationa... -
iPS Cells & Regenerative Medicine Weekly Report July 5, 2026
📄 Weekly Report July 05, 2026 (PDF) — Download Weekly Report July 05, 2026 (PDF) — DownloadDownload 🎙 Podcast July 05, 2026 (MP3) — Play & Download iPS_RegenerativeMedicineEnglishPodcast_20260705.mp3Download View Past Weekly Reports→ -
FDA Manufacturing PreCheck Pilot Program Selects 7 Companies Including Cellares to Streamline and Expedite Cell Therapy Manufacturing Processes
RegMedNet UK Overview The FDA has selected seven companies, including Cellares Corp, FUJIFILM Biotechnologies, and Kriya Therapeutics, for its "Manufacturing PreCheck Pilot Program," designed to streamline cell and gene therapy manufactu... -
Strategic Capital Influx in Gene Therapy: Pfizer Invests in CRISPR Biotech, AstraZeneca Strengthens China Cell Therapy Capabilities
BioPharma Dive USA Overview The gene therapy sector is experiencing a surge in strategic funding and M&A activities from major pharmaceutical companies. Pfizer has invested in CRISPR biotech Caribou Biosciences, while AstraZeneca pla... -
Biopharma M&A Accelerates in H1 2026: Eli Lilly Leads with Over $25 Billion Spend as Big Pharma Bolsters Pipelines
BioPharma Dive USA Overview Biopharmaceutical M&A activity significantly accelerated in the first half of 2026, with over 50 deals transacted. Eli Lilly was notably active, spending over $25 billion and solidifying its position as a ... -
Capricor Therapeutics to Present Positive Five-Year HOPE-2 OLE Data and HOPE-3 Phase 3 Results for Deramiocel in Duchenne Muscular Dystrophy at PPMD 2026 Conference
GlobeNewswire (via Capricor Therapeutics) USA Overview Capricor Therapeutics announced it will present crucial clinical data on Deramiocel, its lead cell therapy candidate for Duchenne Muscular Dystrophy (DMD), at the PPMD 2026 Annual Co... -
FDA Issues Over Six Warning Letters for Unapproved Exosome Therapies in US, Citing Illegal Sales and Unsubstantiated Claims (2024-2026)
Medical Spa Locator USA Overview As of June 2026, no injectable exosome products have received FDA approval in the United States. The FDA has issued over six warning letters between 2024 and 2026 to manufacturers and distributors selling...
